| Autor: |
Frâncio L; Programa de Pós-Graduação em Genética e Biologia Molecular, Universidade Federal do Rio Grande do Sul, Av. Bento Gonçalves, 9500, 90650-001 Porto Alegre, RS, Brazil.; Hospital de Clínicas de Porto Alegre, Laboratório de Células, Tecidos e Genes, Rua Ramiro Barcelos, 2350, 90035-903 Porto Alegre, RS, Brazil., Freitas MV; Programa de Pós-Graduação em Genética e Biologia Molecular, Universidade Federal do Rio Grande do Sul, Av. Bento Gonçalves, 9500, 90650-001 Porto Alegre, RS, Brazil.; Hospital de Clínicas de Porto Alegre, Laboratório de Células, Tecidos e Genes, Rua Ramiro Barcelos, 2350, 90035-903 Porto Alegre, RS, Brazil.; Hospital de Clínicas de Porto Alegre, Núcleo de Bioinformática, Rua Ramiro Barcelos, 2350, 90035-903 Porto Alegre, RS, Brazil., Matte U; Programa de Pós-Graduação em Genética e Biologia Molecular, Universidade Federal do Rio Grande do Sul, Av. Bento Gonçalves, 9500, 90650-001 Porto Alegre, RS, Brazil.; Hospital de Clínicas de Porto Alegre, Laboratório de Células, Tecidos e Genes, Rua Ramiro Barcelos, 2350, 90035-903 Porto Alegre, RS, Brazil.; Hospital de Clínicas de Porto Alegre, Núcleo de Bioinformática, Rua Ramiro Barcelos, 2350, 90035-903 Porto Alegre, RS, Brazil.; Universidade Federal do Rio Grande do Sul, Instituto de Biociências, Departamento de Genética, Av. Bento Gonçalves, 9500, 90650-001 Porto Alegre, RS, Brazil. |
| Abstrakt: |
CRISPR/Cas is being increasingly used for various applications. However, different countries introduce new technologies at different paces and purposes. This study reviews research progress using the CRISPR/Cas system in South America, focusing on health-related applications. The PubMed database was used to identify relevant articles about gene editing with CRISPR/Cas, whereas patents were searched in the Patentscope database. In addition, ClinicalTrials.gov was used to find information on active and recruiting clinical trials. A total of 668 non-duplicated articles (extracted from PubMed) and 225 patents (not all health-related) were found. One hundred ninety-two articles on health-related applications of CRISPR/Cas were analyzed in detail. In 95 out of these, more than 50% of the authors were affiliated with South American institutions. Experimental CRISPR/Cas studies target different diseases, particularly cancer, neurological, and endocrine disorders. Most patents refer to generic applications, but those with clear disease indications are for inborn errors of metabolism, ophthalmological, hematological, and immunological disorders. No clinical trials were found involving Latin American countries. Although research on gene editing in South America is advancing, our data show the low number of national innovations protected by intellectual property in this field. |
